About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 791406, 11 pages
http://dx.doi.org/10.1155/2013/791406
Research Article

Synergistic Effect between Cisplatin and Sunitinib Malate on Human Urinary Bladder-Cancer Cell Lines

1Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro, Vila Real, 5001-801 Vila Real, Portugal
2Genetic Service, Cytogenetic Laboratory, Hospital Center of Trás-os-Montes and Alto Douro, 5000-508 Vila Real, Portugal
3Department of Engineering, CMUTAD, University of Trás-os-Montes and Alto Douro, 5001-801 Vila Real, Portugal
4Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, 4200-072 Porto, Portugal
5Health School, University Fernando Pessoa, 4249-004 Porto, Portugal
6Department of Veterinary Sciences, CECAV, University of Trás-os-Montes and Alto Douro, 5001-801 Vila Real, Portugal

Received 13 May 2013; Accepted 31 October 2013

Academic Editor: Joohun Ha

Copyright © 2013 Regina Arantes-Rodrigues et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Cheung, A. Sahai, M. Billia, P. Dasgupta, and M. S. Khan, “Recent advances in the diagnosis and treatment of bladder cancer,” BMC Medicine, vol. 11, p. 13, 2013. View at Publisher · View at Google Scholar
  2. B. L. Jacobs, J. S. Montgomery, Y. Zhang, T. A. Skolarus, A. Z. Weizer, and B. K. Hollenbeck, “Disparities in bladder cancer,” Urologic Oncology: Seminars and Original Investigations, vol. 30, no. 1, pp. 81–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. E. J. Askeland, M. R. Newton, M. A. O'Donnell, and Y. Luo, “Bladder cancer immunotherapy: BCG and beyond,” Advances in Urology, vol. 2012, Article ID 181987, 13 pages, 2012. View at Publisher · View at Google Scholar
  4. Z. Kirkali, T. Chan, M. Manoharan et al., “Bladder cancer: epidemiology, staging and grading, and diagnosis,” Urology, vol. 66, no. 6, pp. 4–34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Balar, D. F. Bajorin, and M. I. Milowsky, “Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy,” Therapeutic Advances in Urology, vol. 3, no. 3, pp. 107–117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Edeline, Y. Loriot, S. Culine et al., “Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen,” European Journal of Cancer, vol. 48, no. 8, pp. 1141–1146, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Pinto-Leite, R. Arantes-Rodrigues, C. Palmeira et al., “Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer,” Biomedicine & Pharmacotherapy, vol. 67, no. 2, pp. 116–121, 2012.
  8. A. M. Grimaldi, T. Guida, R. D'Attino et al., “Sunitinib: bridging present and future cancer treatment,” Annals of Oncology, vol. 18, no. 6, pp. vi31–vi34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Takahashi, “Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy,” Biological and Pharmaceutical Bulletin, vol. 34, no. 12, pp. 1785–1788, 2011. View at Scopus
  10. J. Bellmunt, J. L. González-Larriba, C. Prior et al., “Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity,” Annals of Oncology, vol. 22, no. 12, pp. 2646–2653, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. J. Gallagher, M. I. Milowsky, S. R. Gerst et al., “Phase II study of sunitinib in patients with metastatic urothelial cancer,” Journal of Clinical Oncology, vol. 28, no. 8, pp. 1373–1379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. T.-C. Chou and P. Talalay, “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors,” Advances in Enzyme Regulation, vol. 22, pp. 27–55, 1984. View at Scopus
  13. A. Niemann, A. Takatsuki, and H.-P. Elsässer, “The lysosomotropic agent monodansylcadaverine also acts as a solvent polarity probe,” Journal of Histochemistry and Cytochemistry, vol. 48, no. 2, pp. 251–258, 2000. View at Scopus
  14. R. Arantes-Rodrigues, R. Pinto-Leite, R. Ferreira et al., “Meloxicam in the treatment of in vitro and in vivo models of urinary bladder cancer,” Biomedicine & Pharmacotherapy, vol. 67, no. 4, pp. 277–284, 2013. View at Publisher · View at Google Scholar
  15. I. Nicoletti, G. Migliorati, M. C. Pagliacci, F. Grignani, and C. Riccardi, “A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry,” Journal of Immunological Methods, vol. 139, no. 2, pp. 271–279, 1991. View at Publisher · View at Google Scholar · View at Scopus
  16. A.-K. Mossberg, B. Wullt, L. Gustafsson, W. Månsson, E. Ljunggren, and C. Svanborg, “Bladder cancers respond to intravesical instillation of HAMLET (human α-lactalbumin made lethal to tumor cells),” International Journal of Cancer, vol. 121, no. 6, pp. 1352–1359, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Arantes-Rodrigues, A. Colaço, R. Pinto-Leite, and P. A. Oliveira, “In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer,” Anticancer Research, vol. 33, no. 4, pp. 1273–1296, 2013.
  18. C. Vasconcelos-Nóbrega, R. Pinto-Leite, R. Arantes-Rodrigues et al., “In vivo and in vitro effects of RAD001 on bladder cancer,” Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 7, pp. 1212–1221, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Pinto-Leite, R. Arantes-Rodrigues, C. Palmeira et al., “Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines,” Journal of Toxicology and Environmental Health, Part A, vol. 75, no. 13–15, pp. 788–799, 2012.
  20. R. Arantes-Rodrigues, R. Pinto-Leite, L. Fidalgo-Gonçalves et al., “Meloxicam synergistically enhances the in vitroeffects of sunitinib malate on bladder cancer cells,” Journal of Applied Biomedicine, vol. 11, pp. 79–92, 2013.
  21. T. Powles, J. Perry, J. Shamash, W. Liu, T. Oliver, and S. Joel, “A comparison of the platinum analogues in bladder cancer cell lines,” Urologia Internationalis, vol. 79, no. 1, pp. 67–72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Zhang, Y. Cheng, X. Ren et al., “NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response,” Oncogene, vol. 31, no. 8, pp. 1055–1064, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Sonpavde, W. Jian, H. Liu, M.-F. Wu, S. S. Shen, and S. P. Lerner, “Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model,” Urologic Oncology: Seminars and Original Investigations, vol. 27, no. 4, pp. 391–399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Y. Yoon, J. S. Lee, B. S. Kim et al., “Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells,” Korean Journal of Urology, vol. 52, no. 1, pp. 55–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. H. H. G. Verbeek, M. M. Alves, J.-W. B. De Groot et al., “The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 6, pp. E991–E995, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. K. C. Cuneo, L. Geng, A. Fu, D. Orton, D. E. Hallahan, and A. B. Chakravarthy, “SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation,” International Journal of Radiation Oncology Biology Physics, vol. 71, no. 3, pp. 873–879, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Pan, J. Tian, X. Zhang, Y. Zhang, and Y. Pan, “Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 9, pp. 1397–1408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. T. J. Abrams, L. B. Lee, L. J. Murray, N. K. Pryer, and J. M. Cherrington, “SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer,” Molecular Cancer Therapeutics, vol. 2, no. 5, pp. 471–478, 2003.
  29. E. S. Chan, A. R. Patel, D. E. Hansel, W. A. Larchian, and W. D. Heston, “Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model,” Urology, vol. 80, no. 3, pp. 736.e1–736.e5, 2012. View at Publisher · View at Google Scholar
  30. Y. Zhao, T. Xue, X. Yang et al., “Autophagy plays an important role in Sunitinib-mediated cell death in H9c2 cardiac muscle cells,” Toxicology and Applied Pharmacology, vol. 248, no. 1, pp. 20–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. G. V. Georgakis, V. Y. Yazbeck, Y. Li, and A. Younes, “The mTOR inhibitor temsirolimus (CCI-779) induces cell cycle arrest and autophagy in Hodgkin lymphoma (HL) cell lines and enhances the effect of the PI3-kinase inhibitor LY294002,” Blood, vol. 108, p. 639, 2006.
  32. J. Liang, S. H. Shao, Z.-X. Xu et al., “The energy sensing LKB1-AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis,” Nature Cell Biology, vol. 9, no. 2, pp. 218–224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Wagner and L. M. Karnitz, “Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival,” Molecular Pharmacology, vol. 76, no. 1, pp. 208–214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. E. W. Lapensee, S. J. Schwemberger, C. R. Lapensee, E. M. Bahassi, S. E. Afton, and N. Ben-Jonathan, “Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase,” Carcinogenesis, vol. 30, no. 8, pp. 1298–1304, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Mueller, M. Schittenhelm, F. Honecker et al., “Cell-cycle progression and response of germ cell tumors to cisplatin in vitro,” International Journal of Oncology, vol. 29, no. 2, pp. 471–479, 2006. View at Scopus
  36. E. G. Konstantakou, G. E. Voutsinas, P. K. Karkoulis, G. Aravantinos, L. H. Margaritis, and D. J. Stravopodis, “Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses,” International Journal of Oncology, vol. 35, no. 2, pp. 401–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. G. N. da Silva, J. P. D. C. Marcondes, E. A. de Camargo, G. A. D. S. Passos Jr., E. T. Sakamoto-Hojo, and D. M. F. Salvadori, “Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine,” Experimental Biology and Medicine, vol. 235, no. 7, pp. 814–824, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Vishnu, G. Colon-Otero, G. T. Kennedy et al., “RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer,” Gynecologic Oncology, vol. 124, no. 3, pp. 589–597, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. S.-Y. Ping, C.-L. Wu, and D.-S. Yu, “Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway{star, open},” Urologic Oncology: Seminars and Original Investigations, vol. 30, no. 5, pp. 652–659, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. E. P. Hui, V. W. Y. Lui, C. S. C. Wong et al., “Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma,” Investigational new drugs, vol. 29, no. 6, pp. 1123–1131, 2011. View at Scopus
  41. Y.-K. Yoon, S.-A. Im, A. Min et al., “Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer,” Cancer Letters, vol. 321, no. 2, pp. 128–136, 2012. View at Publisher · View at Google Scholar · View at Scopus